Piha-Paul, S. A., Matrana, M. R., Brar, G., Villalona-Calero, M., Grynberg, S., Cohen, J., Rottenberg, Y., Lugowska, I. A., Chisamore, M. J., Rowinsky, E. K., Cinamon, G., Tsukerman, P., Paz, K. (2026). Phase 1 study of NTX1088, a first-in-class anti-PVR monoclonal antibody, as monotherapy and combined with pembrolizumab, in patients with advanced solid malignancies.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.2518